BEST Inc. Announces Completion of Going Private Transaction

BEST Inc. Announces Completion of Going Private Transaction

HANGZHOU, China, March 8, 2025 /PRNewswire/ -- BEST Inc. (NYSE: BEST) ("BEST" or the "Company"), a leading integrated smart supply chain solutions and logistics services provider in China and Southeast Asia, today announced the completion of its...

Akeso Announces Completion of Patient Enrollment in The Phase III Clinical Trial of Cadonilimab for Adjuvant Treatment of High-Risk Recurrent Hepatocellular Carcinoma

Akeso Announces Completion of Patient Enrollment in The Phase III Clinical Trial of Cadonilimab for Adjuvant Treatment of High-Risk Recurrent Hepatocellular Carcinoma

HONG KONG, March 6, 2025 /PRNewswire/ -- Akeso, Inc. (9926. HK) ("Akeso" or the "Company") is pleased to announce the completion of patient enrollment for its Phase III registrational clinical trial (COMPASSION-22/AK104-306) evaluating cadonilimab,...

CathWorks Announces the Completion of Enrollment for Landmark ALL-RISE Randomized Controlled Trial

CathWorks Announces the Completion of Enrollment for Landmark ALL-RISE Randomized Controlled Trial

ALL-RISE Study Included Over 1,924 Patients in 59 Sites Across North America, Asia, Europe and the Middle East NEWPORT BEACH, Calif., Jan. 3, 2025 /PRNewswire/ -- CathWorks, a global leader in medical device digital health innovations, announced...

State Grid Kizilsu Kirghiz Autonomous Prefecture Electric Power Supply Company: Aheqi 220 thousand volt power transmission and transformation project is fully connected

State Grid Kizilsu Kirghiz Autonomous Prefecture Electric Power Supply Company: Aheqi 220 thousand volt power transmission and transformation project is fully connected

KIZILSU KIRGHIZ AUTONOMOUS PREFECTURE, China, Nov. 27, 2024 /PRNewswire/ -- Recently, the completion of the last phase of the AN1-AN10 pay-off section of the Kezhou Aheqi 220 thousand volt power transmission and transformation project line marks the...

ArkBio Announces Successful Completion of Enrollment and Dosing for Phase 1 Clinical Study of AK0610, a Preventive Antibody Against Respiratory Syncytial Virus Infection

ArkBio Announces Successful Completion of Enrollment and Dosing for Phase 1 Clinical Study of AK0610, a Preventive Antibody Against Respiratory Syncytial Virus Infection

SHANGHAI, Nov. 25, 2024 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") announced today the successful enrollment and dosing of all participants in a Phase 1 clinical study of AK0610, a fully human monoclonal antibody designed to...

menu
menu